Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

NCT01582568 ·Status: TERMINATED

A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

NCT00152490 ·Status: COMPLETED ·Phase: PHASE3

Study of Cimzia for the Treatment of Ulcerative Colitis

NCT01090154 ·Status: COMPLETED ·Phase: PHASE2

Mucosal Healing Study in Crohn's Disease (CD)

NCT00297648 ·Status: COMPLETED ·Phase: PHASE3

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752 ·Status: TERMINATED ·Phase: PHASE3

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

NCT00152425 ·Status: COMPLETED ·Phase: PHASE3

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

NCT00354367 ·Status: WITHDRAWN ·Phase: PHASE3

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

NCT00160524 ·Status: COMPLETED ·Phase: PHASE3

Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

NCT00307931 ·Status: TERMINATED ·Phase: PHASE3

Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease

NCT00329550 ·Status: COMPLETED ·Phase: PHASE2

CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)

NCT03559660 ·Status: NO_LONGER_AVAILABLE

A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

NCT04643483 ·Status: WITHDRAWN ·Phase: PHASE3

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

NCT01190410 ·Status: COMPLETED ·Phase: PHASE2

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

NCT00333788 ·Status: COMPLETED ·Phase: PHASE3

Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)

NCT00329420 ·Status: COMPLETED ·Phase: PHASE2

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

NCT01817972 ·Status: UNKNOWN ·Phase: PHASE3

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

NCT00356408 ·Status: COMPLETED ·Phase: PHASE3

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

NCT00160706 ·Status: COMPLETED ·Phase: PHASE3

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

NCT02403323 ·Status: TERMINATED ·Phase: PHASE3

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

NCT03169894 ·Status: TERMINATED ·Phase: PHASE1

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

NCT00358683 ·Status: WITHDRAWN ·Phase: PHASE3

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)

NCT01218360 ·Status: COMPLETED

A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis

NCT05796245 ·Status: COMPLETED